Beijing Biostar Pharmaceuticals Co (HKSE:02563) Inventories, Finished Goods: HK$6.09 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02563 Beijing Biostar Pharmaceuticals Co Ltd HKSE:02563
9 GF Score
Price HK$4.30
! 5 Warning Signs
View Full Analysis

What is Beijing Biostar Pharmaceuticals Co Inventories, Finished Goods?

Beijing Biostar Pharmaceuticals Co HKSE:02563 +2.38% 9 Inventories, Finished Goods is HK$6.09 Mil as of Dec. 2025. GuruFocus rates HKSE:02563 with a GF Score™ of 9/100. The stock has 5 warning signs investors should review.

Beijing Biostar Pharmaceuticals Co's quarterly finished goods declined from Dec. 2024 (HK$2.87 Mil) to Jun. 2025 (HK$0.00 Mil) but then increased from Jun. 2025 (HK$0.00 Mil) to Dec. 2025 (HK$6.09 Mil).

Beijing Biostar Pharmaceuticals Co's annual finished goods increased from Dec. 2023 (HK$0.55 Mil) to Dec. 2024 (HK$2.87 Mil) and increased from Dec. 2024 (HK$2.87 Mil) to Dec. 2025 (HK$6.09 Mil).

Beijing Biostar Pharmaceuticals Co Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Beijing Biostar Pharmaceuticals Co's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Biostar Pharmaceuticals Co Inventories, Finished Goods Chart

Beijing Biostar Pharmaceuticals Co Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
2.95 0.55 2.87 6.09

Beijing Biostar Pharmaceuticals Co Semi-Annual Data
Dec22 Dec23 Jun24 Dec24 Jun25 Dec25
Inventories, Finished Goods Get a 7-Day Free Trial 0.55 0.00 2.87 0.00 6.09
HKSE:02563
9GF Score
Beijing Biostar Pharmaceuticals Co Ltd HKSE:02563
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beijing Biostar Pharmaceuticals Co Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of HK$6.09 Mil mean?
Beijing Biostar Pharmaceuticals Co (HKSE:02563) has a Inventories, Finished Goods of HK$6.09 Mil as of Dec. 2025. Finished goods are inventory items that are complete and ready to be sold. View historical data on Beijing Biostar Pharmaceuticals Co and its competitors.
Is Beijing Biostar Pharmaceuticals Co's Inventories, Finished Goods too high?
Beijing Biostar Pharmaceuticals Co's current Inventories, Finished Goods is HK$6.09 Mil. Overall, Beijing Biostar Pharmaceuticals Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Beijing Biostar Pharmaceuticals Co's Inventories, Finished Goods compare to VRTX and REGN?
Beijing Biostar Pharmaceuticals Co's Inventories, Finished Goods of HK$6.09 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Beijing Biostar Pharmaceuticals Co and its competitors. Beijing Biostar Pharmaceuticals Co's current Inventories, Finished Goods is HK$6.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Biostar Pharmaceuticals Co stock overvalued right now?
Beijing Biostar Pharmaceuticals Co (HKSE:02563) has a current Inventories, Finished Goods of HK$6.09 Mil. The current Inventories, Finished Goods is HK$6.09 Mil. Beijing Biostar Pharmaceuticals Co's overall GF Score™ is 9/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Beijing Biostar Pharmaceuticals Co (HKSE:02563), the current Inventories, Finished Goods is HK$6.09 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beijing Biostar Pharmaceuticals Co Business Description

Address 22 Ronghua Middle Road, Suite 1202, Tower B, Yicheng Fortune Center, Beijing Economic-Technological Development Area, Beijing, CHN, 100176
Beijing Biostar Pharmaceuticals Co Ltd is a synthetic biology-driven biopharmaceutical company committed to developing drugs in oncology. It has developed three core technology platforms that focus on the R&D of microbial metabolite new drugs. Its Core Product and 16 out of 19 product candidates are based on a single active pharmaceutical ingredient, namely, Utidelone, which was represented in three formulations of its product portfolio. The company's current clinical trials and programs of the Core Product and product candidates cover indications of advanced breast cancer, advanced non-small cell lung cancer, neoadjuvant for breast cancer, gastric cancer, esophageal cancer, breast cancer brain metastasis, lung cancer brain metastasis, glioblastoma, and other solid tumors.
9GF Score

Get the complete analysis for HKSE:02563

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$4.30
Price